Re Agreement

Ardana PLC
09 November 2005

 ARDANA SIGNS AGREEMENT WITH PHARMACURO TO MARKET STRIANT(TM) SR IN THE NORDIC
                                     REGION



Edinburgh, UK, 9 November 2005;  Ardana plc (LSE:ARA) the emerging
pharmaceutical company focused on improving human reproductive health, today
announces that it has signed an agreement under which Ardana grants Pharmacuro
ApS exclusive rights to market StriantTM SR, Ardana's testosterone replacement
therapy for male hypogonadism, in the Nordic region.



StriantTM SR is a mucoadhesive buccal (gum surface) tablet containing 30mg
testosterone and is indicated as a replacement therapy for male hypogonadism
when deficiency of testosterone has been confirmed.  StriantTM SR is the
first-to-market buccal adhesive tablet and in the UK it is marketed to
urologists and endocrinologists by Ardana's own sales force. Other therapies for
male hypogonadism include injectable formulations of testosterone, oral
preparations, transdermal patches, topical gels and sub-cutaneous implants.



Pharmacuro, established in 2003, is a young, dynamic, pharmaceutical marketing
and distribution company that provides the medical community of Denmark, Sweden,
Norway and Finland with a range of products. Its portfolio, including an
endocrine product for diabetic patients, has been built through in-licensing
agreements and its CEO has played a pivotal role in setting up the Nordic
Urology Advisory Board and the Danish Urology Science Club.



Pharmacuro is an excellent strategic partner for Ardana: its focused sales and
marketing force targets endocrinologists and it has already established strong
relationships in the Nordic region. The market size for testosterone replacement
in the Nordic region is estimated at approximately €3 million per annum.



Pharmacuro expects to launch StriantTM SR in the Nordic market in H1 2006.
Financial terms were not disclosed. Today's announcement follows Ardana's German
marketing contract for StriantTM SR which was agreed with Cytochemia AG in June
2005.



Dr. Maureen Lindsay, Chief Executive of Ardana, said: 'Further to the German
launch of Striant SR last month, we are delighted to extend our marketing
capabilities to include the Nordic region - an important market for StriantTM
SR. Pharmacuro is well positioned to address our target customer base and we
anticipate a strong contribution from our experienced, fast moving Nordic
partner.'



For more information contact:

Ardana                                   Financial Dynamics
Maureen Lindsay                          (corporate/financial media relations)
Tel: + 44 (0) 131 226 8550               Julia Phillips/Davina Langdale
                                         Tel: [phone]

                                         NB Public Relations
                                         (trade/technical media relations)
                                         Nicki Brimicombe
                                         Tel: + 44 (0)1883 732353



About Ardana

Ardana plc is a pharmaceutical company focused on the discovery, development and
marketing of innovative products to improve human reproductive health, a $23.8
billion market.



Since its foundation, Ardana has maintained a broad and balanced portfolio to
manage risk and actively pursues product and technology in-licensing and
out-licensing to maintain a robust pipeline.



Ardana's four lead products are summarised below:



  • StriantTM SR, a testosterone replacement therapy for which Ardana has
    marketing rights in Europe, has already been launched by Ardana through its
    own sales force in the UK as a treatment for men with hypogonadism
  • Teverelix LA, in development for three initial indications (prostate
    cancer in phase II, benign prostatic hyperplasia in phase II and
    endometriosis in phase I)
  • Testo Cream, a trans dermal testosterone delivery system in phase II for
    the treatment of male hypogonadism
  • Invicorp(R), an injectable combination drug treatment for erectile
    dysfunction, already approved in Denmark and for which Ardana has marketing
    and manufacturing rights in Europe. Launch is expected in H2 2006



In addition, Ardana has a strong portfolio of follow-on products in development.
Ardana completed its IPO on the London Stock Exchange in March 2005 raising
£21 million.



For further information please see www.ardana.co.uk



About Pharmacuro

Pharmacuro was established in 2003, based in Denmark and has a sales force
covering Denmark, Sweden, Norway and Finland. The company operates in the Nordic
region and seeks partnerships with other companies to in-licence products in
areas of unmet medical need. The company has identified Endocrinology and
Urology as key therapeutic areas and is already building a product portfolio in
Diabetes.


                      This information is provided by RNS
            The company news service from the London Stock Exchange